Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Cipla Eyes Nov 24 Launch for Liraglutide Biosimilar in PTE Challenge against Novo Nordisk

May 14, 2024

During the first case management of this case in the Federal Court of Australia on 14 May 2024, it became clear that Cipla is challenging the patent term extension (PTE) on Novo Nordisk’s liraglutide formulation patent (AU 2004290862). The 9-month PTE was granted on 4 August 2011 and is due to expire on 26 August 2025.  If Cipla succeeds in its challenge, the expiry date will become 18 November 2024.   

According to submissions made in open Court, pending timely and favourable resolution of its challenge, Cipla plans to launch liraglutide biosimilar on 19 November 2024.   

A three-day substantive hearing has been scheduled for the end of October 2024.  

This follows the Indian launch of a liraglutide biosimilar, Glenmark’s Lirafit® in January this year and the approval in the UK of Biocon’s liraglutide biosimilar in March 2024.